Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Metformin and Esomeprazole in Preterm Pre-Eclampsia
NCT05232994Phase 1Not yet recruiting
- Sponsor
- ChristianaCare
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) and esomeprazole in preeclampsia (2 arms), sponsored by ChristianaCare. Primary endpoint: Soluble fms-like tyrosine kinase 1 at Day 7. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
liquid metformin (Aspargo Labs)esomeprazole
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT05232994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232994.